Overview

Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants

Status:
Terminated
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the feasibility, safety and tolerability of aerosolized lucinactant delivered by nasal continuous positive airway pressure (nCPAP) for the prevention of respiratory distress syndrome (RDS) in premature infants.
Phase:
Phase 2
Details
Lead Sponsor:
Windtree Therapeutics
Treatments:
Pulmonary Surfactants